These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 16271314

  • 1. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
    Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, Foster VJ, Metz A, Rockett CB, Wightman DS.
    Biol Psychiatry; 2005 Oct 15; 58(8):658-67. PubMed ID: 16271314
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression.
    Cox LS, Patten CA, Niaura RS, Decker PA, Rigotti N, Sachs DP, Buist AS, Hurt RD.
    J Gen Intern Med; 2004 Aug 15; 19(8):828-34. PubMed ID: 15242467
    [Abstract] [Full Text] [Related]

  • 3. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.
    Wilens TE, Haight BR, Horrigan JP, Hudziak JJ, Rosenthal NE, Connor DF, Hampton KD, Richard NE, Modell JG.
    Biol Psychiatry; 2005 Apr 01; 57(7):793-801. PubMed ID: 15820237
    [Abstract] [Full Text] [Related]

  • 4. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul 01; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 5. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA.
    J Clin Psychopharmacol; 2006 Oct 01; 26(5):482-8. PubMed ID: 16974189
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of bupropion in winter depression: results of an open trial.
    Dilsaver SC, Qamar AB, Del Medico VJ.
    J Clin Psychiatry; 1992 Jul 01; 53(7):252-5. PubMed ID: 1639745
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S.
    Psychiatry Res; 2009 Sep 30; 169(2):132-8. PubMed ID: 19709754
    [Abstract] [Full Text] [Related]

  • 8. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
    Feighner J, Hendrickson G, Miller L, Stern W.
    J Clin Psychopharmacol; 1986 Feb 30; 6(1):27-32. PubMed ID: 3081600
    [Abstract] [Full Text] [Related]

  • 9. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
    Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U.
    Am J Ther; 2007 Feb 30; 14(3):241-6. PubMed ID: 17515697
    [Abstract] [Full Text] [Related]

  • 10. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG.
    Psychopharmacol Bull; 2003 Feb 30; 37(2):67-78. PubMed ID: 14566216
    [Abstract] [Full Text] [Related]

  • 11. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features.
    Seo HJ, Lee BC, Seok JH, Jeon HJ, Paik JW, Kim W, Kwak KP, Han C, Lee KU, Pae CU.
    Pharmacopsychiatry; 2013 Sep 30; 46(6):221-6. PubMed ID: 23963965
    [Abstract] [Full Text] [Related]

  • 12. Sustained-release bupropion for hospital-based smoking cessation: a randomized trial.
    Simon JA, Duncan C, Huggins J, Solkowitz S, Carmody TP.
    Nicotine Tob Res; 2009 Jun 30; 11(6):663-9. PubMed ID: 19395688
    [Abstract] [Full Text] [Related]

  • 13. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I, Gudayol-Ferré E, Lira-Mandujano J, Herrera-Abarca J, Herrera-Guzmán D, Montoya-Pérez K, Guardia-Olmos J.
    Psychiatry Res; 2008 Jul 15; 160(1):72-82. PubMed ID: 18501971
    [Abstract] [Full Text] [Related]

  • 14. Better patient persistence with once-daily bupropion compared with twice-daily bupropion.
    Stang P, Young S, Hogue S.
    Am J Ther; 2007 Jul 15; 14(1):20-4. PubMed ID: 17303971
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 15; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 16. Bupropion for the treatment of seasonal affective disorder.
    Niemegeers P, Dumont GJ, Patteet L, Neels H, Sabbe BG.
    Expert Opin Drug Metab Toxicol; 2013 Sep 15; 9(9):1229-40. PubMed ID: 23705752
    [Abstract] [Full Text] [Related]

  • 17. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
    Eur Neuropsychopharmacol; 2008 Nov 15; 18(11):803-13. PubMed ID: 18694635
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov 15; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 19. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
    Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.
    J Clin Psychopharmacol; 2007 Aug 15; 27(4):380-6. PubMed ID: 17632223
    [Abstract] [Full Text] [Related]

  • 20. Bupropion SR for relapse prevention: a "slips-allowed" analysis.
    Durcan MJ, Johnston JA, White J, Gonzales D, Sachs DP, Rigotti N, Niaura R.
    Am J Health Behav; 2004 Aug 15; 28(5):456-63. PubMed ID: 15482975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.